Michael J Fusco
Overview
Explore the profile of Michael J Fusco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fusco M, Casak S, Mushti S, Cheng J, Christmas B, Thompson M, et al.
Clin Cancer Res
. 2024 May;
30(15):3100-3104.
PMID: 38809262
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC)...
2.
Donaldson J, Seddiq M, Fusco M, Singla S, Pamuk G, Lee-Alonso R, et al.
Cancer Discov
. 2023 Dec;
13(12):2515-2524.
PMID: 38084090
Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients...
3.
Vellanki P, Ghosh S, Pathak A, Fusco M, Bloomquist E, Tang S, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36796877
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as...
4.
Duke E, Fusco M, DeMoss P, Dilawari A, Pamuk G, Boehmer J, et al.
Cancer Discov
. 2022 Dec;
12(12):2739-2746.
PMID: 36458428
In 2022, cancer drug development continued to progress rapidly despite the lingering COVID-19 pandemic. Highlights of U.S. drug approvals for oncology indications this year include ongoing development in rare diseases...
5.
Fusco M, Knepper T, Balliu J, Cueto A, Laborde J, Hooda S, et al.
Oncologist
. 2022 Mar;
27(1):e9-e17.
PMID: 35305098
Background: Cancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated...
6.
Fusco M, Pina Y, Macaulay R, Sahebjam S, Forsyth P, Peguero E, et al.
Cancer Control
. 2021 Oct;
28:10732748211040013.
PMID: 34620004
Introduction: V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps...
7.
Fusco M, Saeed-Vafa D, Carballido E, Boyle T, Malafa M, Blue K, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250383
Methods: One hundred consecutive patients with pancreatic adenocarcinoma who underwent targeted next-generation sequencing using DNA sequencing with RNA sequencing (n = 47) or without RNA sequencing (n = 53) at...
8.
9.
Pina Y, Fusco M, Macaulay R, Walko C, Peguero E, Evernden B, et al.
J Neurol
. 2019 Nov;
267(3):783-790.
PMID: 31748891
Introduction: A patient who was initially considered to have a glioblastoma (GBM) had molecular analysis, showing that it was a pleomorphic xanthoastrocytoma (PXA). Up to 78% of PXA tumors have...